期刊文献+

白介素-6受体在雌激素替代治疗防治绝经后骨质疏松症中的作用 被引量:1

暂未订购
导出
摘要 目的 探讨白细胞介素 6受体 (IL 6R)在雌激素替代治疗 (ERT)防治绝经后骨质疏松症 (POP)中的作用。方法 选择 86例双侧卵巢切除妇女 ,年龄 34~ 5 3岁 ,其中 4 5例于术后 6个月内开始ERT ,同时口服钙片 ,作为ERT组 ;另 4 1例仅口服钙片 ,作为对照组。随访 19个月。于随访开始和结束时分别空腹抽取静脉血 ,检测血清雌二醇 (E2 )、可溶性IL 6受体α(sIL 6Rα)、可溶性糖蛋白 130 (sgp130 )等指标 ,并同时测定第 2~ 4腰椎 (L2~ 4)及股骨颈骨密度 (bonemineraldensity ,BMD)。结果 ERT组用药后L2~ 4BMD、血清E2 明显高于用药前及对照组 (P <0 0 1) ;sIL 6Rα、sgp130水平均低于用药前及对照组 (P <0 0 1)。sIL 6Rα、sgp130均和E2 呈负相关 (P <0 0 1)。结论 妇女绝经后雌激素水平下降促使IL 6表达增加的同时 ,也使其受体表达增加 ,从而增加骨吸收 ;雌激素通过下调IL 6及其受体的表达 ,可减少因雌激素水平下降而引起的骨吸收增加 ,预防绝经后骨质疏松症的发生。
出处 《江苏医药》 CAS CSCD 北大核心 2004年第5期358-360,共3页 Jiangsu Medical Journal
基金 卫生部科学基金资助课题 (卫 96 2 3 10 )
  • 相关文献

参考文献7

  • 1Kimble RB, Matayoshi AB. Stimmultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period.Endocrinology,1995,136:3054-3061.
  • 2Manolagas SC,Bellido T,Jilka RT.New insights into the cellular,biochemical,and molecular basis of postmenopausal and senile osteoporosis:roles of interleukin-6 and gp130.Int J Immunopharmac,1995,17:109-116.
  • 3Tamura T,Udagawa N,Takahashi N,et al.Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6.Proc Natic Acad Sci,1993,90:11924-11928.
  • 4Song-Cheng Lin,Yamate T,Taguchi Y,et al.Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.J Clin Invest,1997,100:1980-1990.
  • 5Manolagas SC.The role of IL-6 type cytokines and their receptors in bone.Ann N Y Acad Sci,1998,840:194-204.
  • 6刘俊恒,张学光,邱玉华,张毅,李新燕,朱学东.血浆可溶性白细胞介素6受体β糖蛋白链检测试剂盒的研制[J].中华医学检验杂志,1998,21(6):352-354. 被引量:7
  • 7刘俊恒.白细胞介素6受体研究进展[J].国外医学(免疫学分册),1999,22(2):108-109. 被引量:12

共引文献16

同被引文献37

  • 1李楠,林旭,王和鸣,郑良朴,林一萍,沈霖,周琳瑛,钟秀容,林芳.IL-6影响骨髓基质细胞凋亡机理的初步探讨[J].中国骨质疏松杂志,2005,11(1):12-16. 被引量:7
  • 2屠冠军,安贵峰,马立学.核因子与白细胞介素-6在骨质疏松模型中的表达特征[J].中华实验外科杂志,2005,22(9):1091-1093. 被引量:1
  • 3Scheidt-Nave C, Bismar H, Leidig-Bruckner G, etal. Serum interleukin-6 is a major predictor of bone loss in woman specific to the first decade past menopause[J]. J Clin Endocrinol Metab, 2001, 86:2032-2042.
  • 4Manolagas SC. The role of IL-6 type cytokines and their receptors in bone[J]. Ann N Y Acad Sci, 1998, 840:194-204.
  • 5Quaedackers ME, Van Den Brink CE, Wissink S, et al. 4-hydroxy-tamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta[J]. Endocrinology, 2001, 142(3): 1156-1166.
  • 6Helen Brady, Mary Doubleday, Leah M, et al. Differential response of estrogen receptors a and β to SP500263, a novel potent selective estrogen receptor modulator[J]. Mol Pharmacol, 2002,8(3):562-568.
  • 7Ozmen B, Kirmaz C, Aydin K, et al. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-betal and bone turnover markers in the treatment of postmenopausal osteoporosis[J]. Eur Cytokine Netw, 2007, 18(3): 148-153.
  • 8Chae H J, Chae SW, Chin HY, et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts[J]. Bone, 2001, 28:45-53.
  • 9Jia C. Dai, Ping He, Xin Chen, et al. TNF-a and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics[J]. Bone, 2006, 38:509-520.
  • 10Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation[J]. Bone, 2005, 37:601-606.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部